Announcement under Regulation 30 (LODR)-Press Release / Media Release
CSIR-IMTECH in partnership with Zydus Cadila for development of newer drugs for drug-resistant infectious diseases05-07-2018
05-07-2018
Zydus Cadila gets USFDA nod to market 2 drugs
Zydus Cadila has received final approval from the US health regulator to market Nifedipine extended-release tablets and Cholestyramine for oral susp03-07-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Cadila Healthcare Limited has informed the Exchange regarding a press release dated July 03, 2018, titled "Zydus receives final approval from the USFDA for Nifedipine Extended-Release Tablets USP and Cholestyramine for Oral Suspension USP."03-07-2018
Zydus Cadila gets USFDA nod for blood pressure drug
Zydus Cadila today said it has received USFDA approval to market Triamterene and Hydrochlorothiazide tablets, indicated to treat high blood pressure30-06-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Triamterene and Hydrochlorothiazide Tablets USP.30-06-2018
Zydus Cadila gets USFDA nod for erectile dysfunction drug
Zydus Cadila has received approval from the US health regulator to market Tadalafil tablets, used for treating erectile dysfunction, in the American19-06-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives tentative approval from the USFDA for Tadalafil Tablets USP19-06-2018
Announcement under Regulation 30 (LODR)-Investor Presentation
Please find attached the investor presentation to be made to select investors on Monday and Tuesday, June 18 and 19, 2018 at Mumbai.16-06-2018
High base not growth deterrent for Cadila, high launches may drive earning
The stock, which has been trending down due to weak sentiment towards the pharma sector, could provide a good opportunity for investors at current valuations07-06-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
We are pleased to announce that the USFDA inspected the manufacturing facility of our wholly-owned subsidiary, Alidac Pharmaceuticals Ltd., located at SEZ, Ahmedabad from 28th May to 5th June, 2018. At the end of the inspection, no observation (483) is issued. The site manufactures oncology injectables for the regulated markets.06-06-2018